(P112) Precision Medicine for Type 1 Diabetes

Precision medicine offers a new approach to treating Type 1 Diabetes (T1D) by targeting the disease at its root—tailored to individual genetics. This poster showcases Diamyd Medical’s DIAGNODE-3 study, a first phase III precision medicine study in stage 3 T1D, evaluating the GAD65 antigen-specific immunotherapy aimed at preserving beta cell function and improving glycemia. This study is recruiting participants at 12 clinics throughout the US in 2025. www.diagnode-3.com